Skip To Main Content
Inbar Preiss on Muck Rack

Inbar Preiss

Verified
  • Senior Intellectual Property Correspondent, MLex
Brussels
As seen in: MLex, Medium, NewsBreak, The Block, International Journalists Network, The Parliament Magazine, Are We Europe
Journalist covering intellectual property @mlexclusive | Previously crypto regulation reporter @DLNewsInfo & @TheBlock__

Get in touch with Inbar

Contact Inbar, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Inbar Preiss’s Biography

Read Full Bio →

A journalist, editor and writer based in Brussels passionate about bringing human stories to politics. I focus on human rights, cryptocurrency and EU affairs.

Articles

Google faces third EU copyright referral over Gemini training, publisher opt-outs

|
By Inbar Preiss Verified
| MLex Verified
By Inbar Preiss ( October 12, 2026, 15:39 GMT | Insight) -- Google faces a third EU copyright referral over Gemini, as Hungarian judges seek clarity on whether AI training and chatbot responses fall under the same rules, how far copyright exceptions extend and whether publishers must use technical tools to opt out.Google faces a third copyright lawsuit at the EU’s top court over its Gemini chatbot by a Hungarian publisher on whether AI model training is covered by the same rules as the...
Open in Who Shared View Duplicates (9) Issue with article?

Google’s Gemini copyright case back on EU top court calendar

|
By Inbar Preiss Verified
| MLex Verified
By Inbar Preiss ( October 12, 2026, 09:07 GMT | Insight) -- An EU court adviser will deliver an opinion on Nov. 3 in a closely watched Google Gemini copyright case, after an earlier date was dropped. The ruling to follow could clarify AI training and publishers’ rights, despite questions over the referral’s admissibility.An adviser to the EU’s top court is scheduled to deliver an opinion on Nov.
Open in Who Shared View Duplicates (60) Issue with article?

Merck gets cancer drug bar as Halozyme wins cross-border European injunction

|
By Inbar Preiss Verified
| MLex Verified
By Inbar Preiss ( October 9, 2026, 10:51 GMT | Insight) -- A Dutch court has barred Merck’s under-the-skin version of cancer drug Keytruda in eight European countries, upholding Halozyme’s drug-delivery patent and applying EU top court guidance allowing courts to issue cross-border injunctions involving foreign patent rights.US pharmaceutical giant Merck Sharp & Dohme has been barred from manufacturing and marketing an under-the-skin version of its blockbuster cancer drug Keytruda in eight...
Open in Who Shared View Duplicates (395) Issue with article?
See all 763 articles